Clinical trials: Histological Type of Neoplasm
Multiple Myeloma
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA).
- Trial name
- NCT02064387
- Testing
- GSK2857916
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Intractable Epilepsy, Malignant Glioma
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy
This phase IV trial studies the side effects and how well perampanel works in reducing seizure frequency in patients with high-grade glioma and focal epilepsy. Perampanel is a drug used to treat seizures.
- Conditions
- Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma
- Trial name
- NCT04650204
- Testing
- Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of ruxolitinib phosphate when given together with decitabine and to see how well they work in treating patients with acute myeloid leukemia that has come back or is not…
- Conditions
- Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT02257138
- Testing
- Decitabine, Laboratory Biomarker Analysis, Ruxolitinib Phosphate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Carcinoma
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
Results of previous studies suggest that the timing of intravesical mitomycin C administration may impact bladder tumor recurrence rate following radical nephroureterectomy.
- Trial name
- NCT03658304
- Testing
- Mitomycin c
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Florida
Thyroid Gland Anaplastic Carcinoma
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
This randomized phase II trial studies the side effects and how well intensity-modulated radiation therapy (IMRT) and paclitaxel with or without pazopanib hydrochloride works in treating patients with anaplastic thyroid cancer.
- Trial name
- NCT01236547
- Testing
- Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride
- Where
- 130 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00262847
- Testing
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis
- Where
- 632 sites in United States, Canada and 2 more
- Volunteers
- 1,873 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal…
- Trial name
- NCT02231749
- Testing
- Nivolumab, Ipilimumab, Sunitinib
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 1,096 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Vestibular Neuronitis, Vestibular Neuronitis, Bilateral
Recovery of Visual Acuity in People With Vestibular Deficits
The purpose of this study is to determine whether exercises relieve the symptoms of dizziness and imbalance in people with vestibular deficits and improves the ability to see clearly during head movements.
- Conditions
- Vestibular Neuronitis, Vestibular Neuronitis, Bilateral, Vestibular Schwannoma
- Trial name
- NCT00411216
- Testing
- Control exercises, gaze stabilization exercises
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emory University
Follicular Lymphoma, Marginal Zone Lymphoma
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an…
- Trial name
- InMIND (NCT04680052)
- Testing
- tafasitamab, rituximab, lenalidomide
- Where
- 261 sites in United States, Australia and 26 more
- Volunteers
- 654 people
- Sponsor
- Incyte Corporation
Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic).
- Conditions
- Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7
- Trial name
- NCT02339558
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
The primary objective of this study (TOTXVI) is to compare the clinical benefit, the pharmacokinetics, and the pharmacodynamics of polyethylene glycol-conjugated (PEG) asparaginase given in higher dose (HD PEG) versus those of…
- Trial name
- NCT00549848
- Testing
- Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- St. Jude Children's Research Hospital
Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
This phase II trial studies the side effects of cord blood-derived expanded allogeneic natural killer cells (umbilical cord blood natural killer [NK] cells), rituximab, high-dose chemotherapy, and stem cell transplant in treating…
- Conditions
- Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma
- Trial name
- NCT03019640
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cord Blood-derived Expanded Allogeneic Natural Killer Cells
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Amputation Stumps, Neuroma
Pathophysiology of Post Amputation Pain
The purpose of this study is to see how Post Amputation Pain (PAP) affects the body and brain by using sensory testing (such as pinprick testing), taking pictures of your brain (using a functional magnetic resonance imaging…
- Trial name
- PPAP (NCT01632709)
- Testing
- Bupivacaine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shirley Ryan AbilityLab
Peripheral T Cell Lymphoma
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
- Trial name
- NCT03586999
- Testing
- Nivolumab, Etoposide, Prednisolone
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Colorado, Denver
Advanced Angiosarcoma
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for…
- Trial name
- TAPPAS (NCT02979899)
- Testing
- TRC105, Votrient
- Where
- 39 sites in United States, Austria and 6 more
- Volunteers
- 128 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Leiomyosarcoma, Uterine Neoplasm
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy).
- Trial name
- NCT00282087
- Testing
- gemcitabine, docetaxel, doxorubicin
- Where
- 12 sites in United States
- Volunteers
- 47 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Adult T-cell Leukemia-Lymphoma
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
- Trial name
- NCT01626664
- Testing
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Kyowa Kirin, Inc.
Age-Related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with…
- Trial name
- MERLIN (NCT03710564)
- Testing
- Brolucizumab, Aflibercept
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 535 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.